News and Trends 15 Feb 2017 Actelion’s key Drug linked to Deaths, prompting EMA Investigation Johnson & Johnson is certainly counting on its recent acquisition of the European biotech success Actelion to upgrade its top line. Now Actelion’s key product, Uptravi, may be facing some safety issues. One of Actelion’s new products, Uptravi, was launched last January against pulmonary arterial hypertension (PAH) and – with a €150000 ($160,000) price tag – it makes up a […] February 15, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2017 Suffering from House Dust Mite Allergy? A New Therapy is on its Way Allergy Therapeutics, a UK-based biotech company, just announced the approval of its clinical trial application in Spain to advance its next-generation house dust mite allergy vaccine into phase I clinical development. The company Allergy Therapeutics is developing immunotherapeutic vaccines for the treatment of allergies and has been quite successful. Their Pollinex Quattro range of vaccines against […] February 14, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2017 Which European Country is Winning the Race in Clinical Development? A report from the French Association of Biotechnology, France Biotech, could be alerting the French health-care sector this week. The report lists the top European countries leading in clinical development – with France clearly dragging behind other Western European countries. Based on data from the EU Clinical Trials Register, the data compiled by France Biotech reveals which countries are on […] February 14, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 13 Feb 2017 To the Rescue: A Final Phase III Success for Post-Operative Nausea The dopamine antagonist Baremsis is on its way to FDA approval for the treatment and prophylaxis of post-operative nausea & vomiting, after succeeding in a final phase III study. Acacia Pharma, one of our Cambridge top 15 biotechs, is repurposing marketed drugs to provide supportive treatments for post-surgical or cancer patients. Their lead project, Baremsis, is a dopamine antagonist, which Acacia is […] February 13, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 2 Feb 2017 Galapagos kicks off a Phase IIa trial for Cystic Fibrosis After Galapagos and AbbVie expanded their collaboration on cystic fibrosis, Galapagos now announces the start of their Phase IIa trial for a novel cystic fibrosis corrector. Since entering their collaboration with AbbVie on cystic fibrosis (CF) in 2013, Galapagos has received almost €40M in milestone payments from AbbVie. Galapagos now announced the start of a Phase […] February 2, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email